Index

Note: Page numbers of article titles are in boldface type.

A

Acanthocytes (spur cells), 267, 270–271
Achlorhydria, 302
Activin B, 289
Acute chest syndrome, in sickle cell disease, 379
ADAMTS13 protein, 397–398, 404
AIDS
  transmitted in transfusions, 432
  vitamin B<sub>12</sub> deficiency in, 303
Alemtuzumab, 424–425
Alloimmunization, in sickle cell disease, 384
Alopecia, in iron deficiency, 323
Alpha-thalassemia, 365, 371, 417–420
American Association of Blood Banks, 432
American Board of Internal Medicine, 432, 440
American College of Critical Medicine, 439
American College of Physicians, 439–440
American Medical Association, 432
American Society of Apheresis, 398
American Society of Hematology, 432
Aminopterin, folate deficiency induced by, 308–309
Anemia(s)
  aplastic, 418, 421–424
  blood transfusion therapy for, 372, 431–447
  causes of, 277–284
  classification of, 264–265
  compensation for, 264
  definition of, 263
  diagnostic tests for, 265–284
  dyserythropoietic, 309
  evaluation of, 263–284
  hemolytic. See Hemolytic anemias.
  in copper deficiency, 280, 418, 420
  in endocrine disease, 279
  in myelodysplastic syndrome. See Myelodysplastic syndromes.
  in nutritional deficiencies, 279–280
  in paroxysmal nocturnal hemoglobinuria, 418, 420–421
  in plasma cell myeloma, 281
  in renal disease, 277–278
  in sickle cell disease, 280, 375–393, 435
  in thrombotic microangiopathy, 395–415
Anemia(s) (continued)

iron deficiency, 279, 319–332
megaloblastic, 297–317
microcytic, 301
of inflammation, 278–279, 285–296
pernicious, 300, 302, 305. See also Megaloblastic anemias.
pure red cell, 334–337, 418, 424–426
sideroblastic, 309
spur cell, 426
symptoms and signs of, 263–264
unusual, 417–429

Anisocytosis, 266–267
Anisoipoikilocytosis, 270
Ankyrin defects, 366
Antibodies, in autoimmune hemolytic anemia, 351–352
Antithymocyte globulin
for aplastic anemia, 422, 424
for pure red cell aplasia, 425
Aplastic anemia, 418, 421–424
Aplastic crisis, in sickle cell disease, 379
Aplastic events, in congenital hemolytic anemia, 363
Aspirin, iron deficiency due to, 322
Asplenia, in sickle cell disease, 382
Athletes, iron deficiency in, 321
Atrophic gastritis, pernicious anemia in, 300, 302, 305
Atypical hemolytic uremic syndrome, 399–400
Australian Society of Blood Transfusion, 439
Autoagglutination, 274
Autoimmune gastritis, pernicious anemia in, 300, 302, 305
Autoimmune hemolytic anemia, 351–359
autoantibodies in, 351–352
clinical presentation of, 352, 354–355
heterogeneity of, 351–353
incidence of, 351
primary, 352–353
secondary, 352–353, 355
treatment of, 355–357
Azacitabine, for myelodysplastic syndrome, 337–341
Azathioprine
for autoimmune hemolytic anemia, 356
pure red cell aplasia due to, 424–425

B

Bariatric surgery
iron deficiency in, 321
vitamin B12 deficiency in, 279
Basophilic stippling, 267, 274
Best practices alerts, 440
Biliary disease, in sickle cell disease, 379
Bilirubin, 281, 314
Bite cells (degmacytes), 267, 272
Blind loop syndrome, 305
Blister cells, 267, 273
Blood and marrow transplantation, 340–345
Blood smear assessment, 266–274, 354–355
Blood transfusion therapy
  alternatives to, 432
  clinical practice guidelines for, 438–440
  errors in, 432
  for pediatric patients, 433, 435
  indications for, 433, 435
  preventive strategies in, 432–433
  risks of, 432–434
    for aplastic anemia, 424
    for sickle cell disease, 382–384
    for thalassemia, 372, 419–420
  utilization improvement for, 440–442
BMT Clinical Trials Network study, 344–345
Bone marrow examination, 276
Bone morphogenic protein, 287–288
Bortezomib, 405
British Committee for Standards in Hematology, 439
Burns, hemolytic anemia in, 418, 427
Burr cells, 267, 271–272

C
C3 convertase, 400
Canadian Medical Association, 439
Cancer, 286
Caplacizumab, 405
Cardiac output, in anemia, 264
Cardiovascular disease
  in thrombotic thrombocytopenic purpura, 397
  transfusions for, 435–436
Castleman disease, 292
C/EBPα, 288–289
Celiac disease
  copper deficiency in, 420
  folate deficiency in, 306
  iron deficiency in, 321, 327
Chemotherapy
  folate deficiency induced by, 308–309
    for myelodysplastic syndromes, 341–345
Children’s Oncology Group, 435
Chlorpropamide, pure red cell aplasia due to, 424–425
Choosing Wisely campaign, 440
Classical thrombotic thrombocytopenic purpura, 396–398
Clopidogrel, thrombotic microangiopathy due to, 402
Clostridium perfringens infections, 418, 426
Coagulation-mediated microangiopathy, 401
Cobalamin deficiency. See Vitamin B₁₂ deficiency.
Cold agglutinins, 274
Cold antibodies, in autoimmune hemolytic anemia, 352, 355–357
Cold intolerance, in iron deficiency, 322
College of American Pathologists, 439
Complement C3b test, 354
Complement pathway, in hemolytic uremic syndrome, 400
Complete blood count, 266
Congenital hemolytic anemia, 361–374
  classification of, 362
  clinical presentation of, 362–363
  differential diagnosis of, 364
  enzymopathies in, 365–370
  hemoglobinopathies in, 370–372
  laboratory features of, 363–365
  membranopathies in, 365–367
  types of, 362
Congenital thrombotic thrombocytopenia purpura, 398–399
Coombs test, 281
Coombs-negative antibodies, in autoimmune hemolytic anemia, 352
Copper, accumulation of, 418, 426–427
Copper deficiency, 280, 418, 420
Core biopsy, of bone marrow, 276
Corticosteroids, for autoimmune hemolytic anemia, 355
Costs, of transfusion therapy, 441
Coulter, Wallace, 266
C-reactive protein, 285–286
Critical decision support, for transfusions, 440
Critical illness, 285–286
Cubilin protein, 303
Culture, cell, 277
Cyanocobalamin deficiency. See Vitamin B₁₂ deficiency.
Cyclophosphamide
  for aplastic anemia, 424
  for autoimmune hemolytic anemia, 355–356
  for pure red cell aplasia, 425
  for thrombotic thrombocytopenic purpura, 398
Cyclosporine
  for aplastic anemia, 422, 424
  for myelodysplastic syndrome, 337–341
  for pure red cell aplasia, 334–337, 425
  for thrombotic thrombocytopenic purpura, 398
  thrombotic microangiopathy due to, 402
Cytogenetics, 276–277
Cytokines, 289
Cytopenias, hydroxyurea-induced, 386

D
Daclizumab, 424
Dacrocytes (tear drop cells), 267, 270
Dactylitis, in sickle cell disease, 379
Danazol, for myelodysplastic syndrome, 337–341
Deferasirox, for sickle cell disease, 384–385
Degmacytes (bite cells), 267, 272
Dexamethasone, for autoimmune hemolytic anemia, 355
Diacylglycerol kinase defects, 401
Diarrhea, in hemolytic uremic syndrome, 399–401
Diet
  folate deficiency in, 306
  for iron deficiency, 324–325
  iron content of, 319–320
Dihydrofolate reductase deficiency, 308
2,3-Diphosphoglycerate, in anemia, 264
Direct antiglobulin (direct Coombs or DAT), 354–355
Divalent metal transporter, 319–320
DNA, synthesis of, defects of, 299
Donath-Landsteiner antibodies, 352
Drug(s)
  aplastic anemia due to, 423
  pure red cell aplasia due to, 424–425
Drug-related thrombotic microangiopathy, 402
Dyserythropoietic anemia, congenital, 309

E

Echinoctyes, 267
Echinocytes (burr cells), 267, 271–272
Eculizumab
  for hemolytic uremic syndrome, 401
  for paroxysmal nocturnal hemoglobinuria, 421
Elderly persons, transfusions for, 436
Electronic health records, 441
Electrophoresis, for thalassemia, 280
Elliptocytes, 267, 269–270
Elliptocytosis, hereditary, 365, 367
Elthrombopag, 424
Enteritis, folate deficiency in, 306
Enzymopathies, in congenital hemolytic anemia, 365–370
Erythроferrone, 288
Erythroid leukemia, acute, 309
Erythropoiesis, 286
Escherichia coli, in hemolytic uremic syndrome, 379
Exchange transfusions, for sickle cell disease, 383–384
Exercise, iron deficiency in, 321

F

Factor H, 400
Factor I, 400–401
Fatigue, in iron deficiency, 322
Fatty liver of pregnancy, 403–404
Ferroportin, 286, 319–320
Ferrous sulfate, for iron deficiency, 324
Fertility complications, in sickle cell disease, 381
Fish tapeworm, vitamin B₁₂ deficiency in, 303, 305
Fluorescence in situ hybridization, 277
FOCUS trial, 436, 438
Folate deficiency, 279–280. See also Megaloblastic anemias.
  causes of, 304–308
  clinical features of, 306
  drug-induced, 308–309
  in inborn errors of metabolism, 307–308
  laboratory tests for, 300–301, 307
  neural tube defects due to, 306–307
  pathogenesis of, 305
Folinic acid rescue, 308–309
Folistatin, 291

G
Gait abnormalities, in vitamin B₁₂ deficiency, 304
Gallstones, in congenital hemolytic anemia, 363, 367
Gastrectomy, vitamin B₁₂ deficiency in, 279, 305
Gastritis, atrophic, pernicious anemia in, 300, 302, 305
Gastrointestinal bleeding, iron deficiency and, 322
Gastrointestinal disorders, in thrombotic thrombocytopenic purpura, 397
GBT440, for sickle cell disease, 387
Gemcitabine, thrombotic microangiopathy due to, 402
Gilbert syndrome, 363
Glucose-6-phosphate dehydrogenase deficiency, 365, 368–369
Glycosylphosphatidylinositol defects, 421
Graft-versus-leukemia effect, 344–345

H
Haptocorrin, 300
Haptoglobin, 280–281, 354
Heart failure, in iron deficiency, 322
Heinz bodies, 272
Helicobacter pylori infections, 302, 321
HELLP syndrome, 403–404
Helmet cells, 267
Hematologic disorders, in thrombotic thrombocytopenic purpura, 396–397
Hematopoietic stem cell transplantation. See Stem cell transplantation.
Hemoglobin Bart, 417–419
Hemoglobin E disease, 419
Hemoglobin H disease, 371, 418–420
Hemoglobin level, in anemia, 263–264
Hemoglobin S, 375–378
Hemoglobinopathies. See also Sickle cell disease.
### Index

**in congenital hemolytic anemia**, 370–372
- testing for, 280

**Hemoglobinuria**
- in autoimmune hemolytic anemia, 354
- nocturnal paroxysmal, 418, 420–421

**Hemojuvelin**, 287–288

**Hemolytic anemias**, 280–281
- acquired, 418, 426–427
- autoimmune, 351–359
- congenital, 361–374
- folate deficiency in, 307
- microangiopathic, 418, 426–427
- paroxysmal nocturnal hemoglobinuria, 418, 420–421
- tests for, 280–281

**Hemolytic events, in congenital hemolytic anemia**, 362

**Hemolytic uremic syndrome**, 399–401

**Hepatitis C**, transmitted in transfusions, 432

**Hepcidin**, 287–292, 320

**Hereditary folate malabsorption**, 307

**HIV infection**
- transmitted in transfusions, 432
- vitamin B<sub>12</sub> deficiency in, 303

**Homocystinuria**, 304

**Howell-Jolly bodies**, 267, 274

**Hydroxyurea**
- folate deficiency induced by, 308–309
- for sickle cell disease, 385–386

**Hyperbilirubinemia**
- in congenital hemolytic anemia, 362
- in pyruvate kinase deficiency, 370

**Hyperchlorhydria**, vitamin B<sub>12</sub> deficiency in, 302–303

**Hyperhemolysis**, in sickle cell disease, 379

**Hyperhomocysteinemia**, 308

**Hypertension, in pregnancy**, 403–404

**Hypochromia**, 266, 268

**Hypogonadism**, 279

**Hypomethylating agents, failure of, in myelodysplastic syndromes**, 337–341

**Hypothyroidism**, 279

---

I

**Ileitis**, vitamin B<sub>12</sub> deficiency in, 303

**Imerslund-Graesbeck syndrome**, 303

**Immunoglobulin G**, in autoimmune hemolytic anemia, 351–352, 355–357

**Immunoglobulin M**, in autoimmune hemolytic anemia, 352, 355–357

**Immunosuppressive drugs**
- for aplastic anemia, 422, 424
- for autoimmune hemolytic anemia, 356

**Infections**
- in congenital hemolytic anemia, 369
- in sickle cell disease, 381
Infections (continued)
- transmitted in transfusions, 432–434

Inflammation, anemia of, 278–279, 285–296
- definition of, 285
- epidemiology of, 285–286
- experimental models of, 286–289
- pathophysiology of, 286–289
- treatment of, 290–292

Inflammatory bowel disease, iron deficiency in, 321

Interleukins, 285–286, 289
- inhibitors of, 290–292

International Prognostic Scoring System Score, for myelodysplastic syndromes, 337–341

Intrinsic factor, 300, 302–303

Iron
- absorption of, 324–326
- chelated, for sickle cell disease, 384–385
- metabolism of, 319–320
- recommendations for, 320
- sequestration of, 286, 289

Iron deficiency anemia, 319–332
- diagnosis of, 323–324
- epidemiology of, 320–322
- etiologies of, 320–322
- iron metabolism and, 319–320
- symptoms of, 322–323
- tests for, 279
- treatment of, 324–327

Iron overload, in thalassemia, 420

Iscocitrate, 291

Isoniazid, pure red cell aplasia due to, 424–425

J

Jehovah’s Witness group, transfusion outcomes and, 435

K

Kaiser Permanente Northern California, 441

Karyotyping, 277

Kidney Disease Improving Global Outcomes, 439

Kidney dysfunction or failure
- in hemolytic uremic syndrome, 379, 399–401
- in thrombotic thrombocytopenic purpura, 397

L

Lactate dehydrogenase, 281

Lactoferrin, 289

Laser light scatter test, 266

LDN-193189, 290, 292

Lenalidomide, 337–341
Leukemia
- acute erythroid, 309
- acute lymphocytic, 341–345
- chronic lymphocytic, 341–345
- myeloid, 282
  - versus megaloblastic anemia, 301
Leukocytosis, in sickle cell disease, 378
Leukopenia, in megaloblastic anemia, 299
Lipocalin 2, 289
Lipopolysaccharide, 288–289
Liver disease
  - hemolytic anemia in, 418, 426
  - in pregnancy, 403–404
  - in sickle cell disease, 379

M
Macrocytic anemia, 264, 266, 272
Macrophages, in iron salvage, 287
Magnetic resonance imaging, for sickle cell disease, 384–385
Malabsorption, in megaloblastic anemia, 299
Malnutrition, vitamin B₁₂ deficiency in, 303
MD Anderson Scoring System, for myelodysplastic syndromes, 337–341
Mean corpuscular hemoglobin, 275
Mean corpuscular hemoglobin concentration, 275
Mean corpuscular volume, 275
Megakaryocytes, abnormal, 298
Megaloblastic anemias, 297–317
  - acute, 301–302
  - attenuated, 301
  - causes of, 297–301
    - drug-induced, 308–309
    - folate deficiency, 304–308
    - list of, 298
    - rare, 309
      - vitamin B₁₂ deficiency, 302–305
  - clinical features of, 299
  - compensation for, 299–301
  - congenital, 309
  - differential diagnosis of, 301–302
  - laboratory tests for, 299–301
  - pathogenesis of, 298–299
  - refractory, 309
    - thiamine-responsive, 309
Membrane cofactor protein (CD46), 400
Membranopathies, in congenital hemolytic anemia, 365–367
Menstruation, iron deficiency and, 320–321
Mentzer index, for thalassemia, 280
Metabolism-mediated microangiopathy, 401
Methionine synthase, 304, 308
Methotrexate, folate deficiency induced by, 308–309
Methyl prednisolone, for thrombotic thrombocytopenic purpura, 398
Methylene tetrahydrofolate reductase deficiency, 308
Methylmalonic acid, 300, 304
Methylprednisolone, for autoimmune hemolytic anemia, 355
Microangiopathic hemolytic anemias, 418, 426–427
Microangiopathy, thrombotic, 395–415
Microcytic anemia, 264, 266, 268, 301, 419
MINT Trial, 438
Mitomycin C, thrombotic microangiopathy due to, 402
Molecular tests, 276–277
Monocytic anemia, 266
Mortality, in inflammation, 286
Multicenter Study of Hydroxyurea, 385
Multisystem organ failure
  in sickle cell disease, 380
  in thrombotic microangiopathy, 403
Mycophenolate mofetil, 356, 424
Myelodysplastic syndromes, 281–283, 309, 333–350
  clinical vignettes of, 333–350
  blood and marrow transplantation, 341–345
  diagnostic considerations, 334–337
  hypomethylating agent failure, 337–341
  testing for, 281–283
  therapy-related, 341–345
Myeloid differentiation factor2-TLR complex, 289
Myeloma, plasma cell, 281
Myelopathy, in copper deficiency, 420

N
National Blood Authority Australia, 439
National Cancer Center Network, 439
National Institutes of Health Consensus Conference, 439
Neural tube defects, to folate deficiency, 306–307
Neurologic disorders
  in megaloblastic anemia, 299
  in thrombotic thrombocytopenic purpura, 396
  in vitamin B₁₂ deficiency, 304
Neutropenia
  in aplastic anemia, 421–422
  in copper deficiency, 420
Neutrophils, 268, 282
Next-generation sequencing, 277
Nocturnal hemoglobinuria, paroxysmal, 418, 420–421
Nonsteroidal anti-inflammatory drugs, iron deficiency due to, 322
Normocytic anemia, 264, 266
NOX-H94, 290, 292

O
Obesity, 286
Ocular disorders, in sickle cell disease, 380
Index

Osmotic fragility test, 366
Ovalocytes, 267, 270
Oxygen delivery, in anemia, 264

P
p53, 288–289
Pain, in sickle cell disease, 379–380
Pancreatic insufficiency, vitamin B$_{12}$ deficiency in, 303
Pancytopenia, in aplastic anemia, 421–422
Paresthesias, in vitamin B$_{12}$ deficiency, 304
Paroxysmal cold hemoglobinuria, 352
Paroxysmal nocturnal hemoglobinuria, 418, 420–421
Parovirus B19 infections, 424–426
Patient Blood Management initiative, 432
Pediatric patients, transfusion therapy for, 433
Pencil cells, 270
Peripheral blood smear assessment, 266–274
Peripheral neuropathy, in vitamin B$_{12}$ deficiency, 304
Permetrexed, folate deficiency induced by, 308–309
Pernicious anemia, 300, 302, 305. See also Megaloblastic anemias.
Phenytoin, pure red cell aplasia due to, 424–425
Photospectrometry, 266
Physician order entry, for transfusions, 440
Plasma cell myeloma, 281
Plasma exchange therapy
  for congenital thrombotic thrombocytopenic purpura, 398–399
  for hemolytic uremia syndrome, 401
  for thrombotic microangiopathy, 402
  for thrombotic thrombocytopenic purpura, 397–398
Plasma volume, in anemia, 264
Plasminogen, defects in, 401
Platelets, 268
  transfusion of, for aplastic anemia, 424
Poikilocytosis, 266–267
Polychromatophilic red cells, 272–273
Polyglutamyl synthase, 308–309
Polymerase chain reaction, 277, 334–337
Prednisone
  for autoimmune hemolytic anemia, 355
  for pure red cell aplasia, 425
Preeclampsia, 403–404
Pregnancy
  folate requirements in, 306–308
  iron deficiency in, 320–322
  thrombotic microangiopathy in, 403–404
Premature in Need of Transfusion study, 435
Priapism, in sickle cell disease, 379, 381
Proaerolysin, 421
Protein kinase-C associated protein, defects in, 401
Proteinuria, in pregnancy, 403–404
Index

Protoporphyrin, 285
Psychiatric disorders, in vitamin B_{12} deficiency, 304
Pulmonary disorders, in thrombotic thrombocytopenic purpura, 397
Pulmonary hypertension
   in sickle cell disease, 381
   iron deficiency and, 322–323
Purchase acquisition costs, for transfusions, 441
Pure red cell aplasia, 334–337
Purpura, thrombocytopenic, 395–415
Pyruvate kinase deficiency, 365, 369–370

R
Red cell(s), 264–265
   indices, 275
   nucleated, 267, 272–273
   pure aplasia of, 334–337, 418, 424–426
   shape of, 266–274
   size of, 266
   smear test of, 266–274
Restless leg syndrome, 323
Reticulocyte count, 274–275
   in autoimmune hemolytic anemia, 354
   in congenital hemolytic anemia, 362–364, 368–369
   in pure red cell aplasia, 424–425
   in sickle cell disease, 385
Reticulocytes, 267
Rituximab
   for autoimmune hemolytic anemia, 355–357
   for pure red cell aplasia, 425
   for thrombotic thrombocytopenic purpura, 398
Rivipansel, for sickle cell disease, 386
Rouleaux, 272, 274

S
Schistocytes, 267
Selection blockers, for sickle cell disease, 386
Sepsis, in sickle cell disease, 379
Septic Shock trial, 436
Shiga toxin, in sickle cell disease, 379
Sickle cell disease, 365, 375–393
   definition of, 376
   epidemiology of, 376
   pathophysiology of, 376–378
   severity of, 378–381
   testing for, 280
   transfusions for, 435
   treatment of, 382–387
Sideroblastic anemia, 309
Sirolimus, for autoimmune hemolytic anemia, 356
Situximab, 290, 292
Small intestinal disorders
    folate deficiency in, 306
    vitamin B₁₂ deficiency in, 303
Society for the Advancement of Blood Management, 439
Society of Cardiovascular Anesthesiologists, 439
Society of Critical Care Medicine, 439
Society of Thoracic Surgeons, 439
Spectrin defects, 366
Spherocytes, 267
Spherocytosis, hereditary, 364–366
Splenectomy
    for autoimmune hemolytic anemia, 355–356
    for congenital hemolytic anemia, 367
Sprue, folate deficiency in, 306
Spur cell(s), 267, 270–271
Spur cell anemia, 426
Stack of coins appearance, 272
Stanford Health Plan, 440
Stat3, 288–289
Stem cell transplantation
    for aplastic anemia, 422, 424
    for sickle cell disease, 386
    thrombotic microangiopathy in, 402–403
Storage iron, 279
Stroke, in sickle cell disease, 380

T
Tacrolimus, thrombotic microangiopathy due to, 402
Target cells, 267, 270, 273
Tear drop cells (dacrocytes), 267, 270
Thalassemia, 280, 365, 370–372, 417–420
Thiamine-responsive megaloblastic anemia, 309
Thrombocytopenia
    in aplastic anemia, 421–422
    in megaloblastic anemia, 299, 301–302
    in thrombotic microangiopathy, 395–415
Thrombocytopenic microangiopathy, hemolytic uremic syndrome, 399–401
Thrombomodulin, defects in, 401
Thrombophilia, in paroxysmal nocturnal hemoglobinuria, 418, 420–421
Thrombosis, in congenital hemolytic anemia, 363
Thrombotic microangiopathy, 395–415
    classical thrombotic thrombocytopenia purpura, 396–398
    coagulation-mediated microangiopathy, 401
    congenital thrombotic thrombocytopenia purpura, 398–399
    drug-related thrombotic microangiopathy, 402
    pregnancy-related, 403–404
    metabolism-mediated microangiopathy, 401
    stem cell transplant-related, 402–403
    treatment of, 404–405
Thrombotic thrombocytopenic purpura, 396–399
Ticlopidine, thrombotic microangiopathy due to, 402
TITRe2 trial, 437–438
TMPRSS6, 287–288, 322
Tocilizumab, 290
Total iron binding capacity, 323
TOTAL trial, 435
TRACS (Transfusion Requirements after Cardiac Surgery) trial, 436–438
Transferrin, 285–286, 319–320
Transferrin receptor, 323
Transfusion Requirements after Cardiac Surgery (TRACS) trial, 436–438
Transfusion Requirements in Critical Care (TRICC) trial, 436, 438
Transfusion therapy. See Blood transfusion therapy.
Transfusion-related acute lung injury, 432
Transplantation
  blood and marrow, for myelodysplastic syndromes, 340–345
  stem cell
    for aplastic anemias, 422, 424
    for thrombotic microangiopathy, 386
    thrombotic microangiopathy in, 402–403
TRICC (Transfusion Requirements in Critical Care) trial, 436, 438
Trimethoprim, folate deficiency induced by, 309

U

UGT21A1 gene, 378
Ulcers, in sickle cell disease, 380
Upshaw-Schulman syndrome (congenital thrombotic thrombocytopenia purpura), 398–399
Uremia, 289
Utilization improvement, for blood transfusion therapy, 440–442

V

Vaccinations, in sickle cell disease, 382
Valproic acid, pure red cell aplasia due to, 424–425
Vascular malformations, iron deficiency due to, 321–322
Vascular necrosis, in sickle cell disease, 380
Vegetarian diets, vitamin B₁₂ deficiency in, 303
Ventricular assist devices, 426
Vepoloxamer, for sickle cell disease, 386–387
Vincristine, for thrombotic thrombocytopenic purpura, 398
Vitamin B₁₂ deficiency, 279. See also Megaloblastic anemias.
  causes of, 302–304
  clinical features of, 299, 304
  laboratory tests for, 299–301
  microangiopathy, 401
  treatment of, 304
Vitiligo, in megaloblastic anemia, 299
von Willebrand multimers, in thrombotic thrombocytopenic purpura, 397–398
W
Warm antibodies, in autoimmune hemolytic anemia, 351–352, 355–357
Weakness, in megaloblastic anemia, 299
Wilson disease, 418, 426–427
Wintrobe classification, 264–265
World Health Organization, Classification-based scoring system, for myelodysplastic syndromes, 337–341

Z
Zidovudine, folate deficiency induced by, 308–309
Zika virus, 432
Zinc protoporphyrin, 323
Zinc transporter, 420
Zollinger-Ellison syndrome, vitamin B₁₂ deficiency in, 302–303